Compare Jones Lang LaSalle Inc (JLL) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

JLL trades at $298.93, up 0.77% on the day, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue and net income have grown steadily, reaching $26.12B and $792.10M in 2025, respectively, while valuation ratios like a P/E of 14.54 and P/S of 0.53 appear attractive relative to historical norms.

The outlook is positive, supported by analyst consensus favoring a buy rating and a price target of $450.50, implying significant upside. Risks include exposure to real estate market cycles and competitive pressures, but JLL's expanding cash flow and strategic acquisitions in high-growth areas like data centers provide a solid foundation for continued growth.

DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.

The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.